Dr. Renee P. Tannenbaum Ph.D. serves as Independent Director of the Company. She has served as a member of our board of directors since February 2015. Dr. Tannenbaum currently serves as Vice President of Global Alliances at Halozyme, Inc., where she is responsible for leading the team that executes the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012 and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management. Dr. Tannenbaum served as a director to Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc. a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014 and Immune Pharmaceuticals, Inc., a publicly-traded company, from August 2011 to October 2012. Dr. Tannenbaum retains a faculty position at the University of the Sciences’ Mayes College of Healthcare Business and Policy and serves as the Dean’s Professor.
What is Renee P. Tannenbaum's net worth?
The estimated net worth of Renee P. Tannenbaum is at least $266,800.00 as of September 15th, 2022. Dr. Tannenbaum owns 10,000 shares of Zogenix stock worth more than $266,800 as of April 24th. This net worth evaluation does not reflect any other investments that Dr. Tannenbaum may own. Learn More about Renee P. Tannenbaum's net worth.
How do I contact Renee P. Tannenbaum?
Has Renee P. Tannenbaum been buying or selling shares of Zogenix?
Renee P. Tannenbaum has not been actively trading shares of Zogenix during the last quarter. Most recently, Renee P. Tannenbaum sold 5,305 shares of the business's stock in a transaction on Monday, November 29th. The shares were sold at an average price of $11.72, for a transaction totalling $62,174.60. Learn More on Renee P. Tannenbaum's trading history.
Who are Zogenix's active insiders?